The standard treatment for Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD) is a regimen of psychotherapy combined with medications to reduce symptoms of depression and minimize the cravings for alcohol.
The purpose of this study is to determine if Psilocybin Assisted Therapy (PAT) can be used to safely and effectively treat AUD and MDD when they occur together in individuals.
Eligibility Criteria
- Age Range: 18-64 years old
- Diagnosed with Major Depressive Disorder and Alcohol Use Disorder
- Are not pregnant or breastfeeding
- Have not used illicit drugs heavily over the past 6 months
- Have not used hallucinogens in past 5 years and used 10 or less times lifetime
- Willing to attend study visits over 6 months
What does the study involve?
- Number of contacts: 10+ sessions
- Compensation offered: Yes
Investigator(s): Dr. Bernard Le Foll
Full Study Title: Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial
Contact Information:
E-mail: psilocybin.mdd-aud@camh.ca
REB number: 2023/071
REB Approval Expiry Date: February 24, 2027
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.